Use of any live vaccines within  weeks of initiation of study treatment
Use of any live vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within  weeks of initiation of study treatment.
Use of live vaccines within four weeks of starting abatacept
Vaccination with live attenuated vaccines within  weeks of first study agent administration
Use of any live vaccines against infectious diseases within  weeks of initiation of study treatment.
Administration of live vaccines within  days prior to enrollment
Received live attenuated vaccines within  days of first dose.
Receipt of live-virus vaccines within  days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Vaccine administration of live vaccines within  days of enrollment
Receipt of live-virus vaccines within  days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Current or recent treatment with therapeutic antibiotics, live attenuated vaccines or systemic immunostimulatory/immunosuppresive medication
Vaccination with live attenuated vaccines within  weeks of first study agent administration
Receipt of live-virus vaccines within  days prior to the initiation of study treatment
Use of non-oncology vaccines containing live virus for prevention of infectious diseases within  weeks prior to study drug
Live vaccines within  days prior to study pre-registration
Receipt of live-virus vaccines within  days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Live vaccines are not permitted within  days of study registration
Newly diagnosed MCL: Major surgery within  weeks or vaccination with live attenuated vaccines within  weeks of the first dose of study drug
Treatment with a live virus vaccine during the  months prior to baseline visit; no live vaccines will be allowed throughout the course of this study
Use of any live vaccines against infectious diseases within  weeks of initiation of study treatment. Non-live vaccination (eg, influenza) are permitted anytime during treatment
Live-virus vaccines =<  days prior to registration
Previous treatment with radiotherapy, or immunotherapeutic agents, or receipt of live vaccines in the  weeks prior to study drug administration;
Use of any live vaccines within  weeks of initiation of study treatment.
Administration of live attenuated vaccines within  weeks of study enrollment.
Vaccination with live attenuated vaccines within  weeks of first study agent administration
TREATMENT: Patients who have received live attenuated vaccines within  week of the start are ineligible to receive everolimus
Patients who have received a live, attenuated vaccines within  weeks of first dose of drug
Vaccination with live, attenuated vaccines within  weeks of first dose of study drug
received live vaccines.
Participants in Phase b Stage Only: Vaccination with live vaccines within  months before Cycle , Day 
Administration of live attenuated vaccines within eight weeks of start of study treatment (day -) and throughout the study
Receipt of live-virus vaccines within  days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Administration of live vaccines =<  days prior to registration; note: patients may not receive any viral immunizations during the study and for  days after the last dose of Reolysin
Patients who have received live attenuated vaccines within  week of start of everolimus and during the study
Use of live or live attenuated vaccines within  days prior to randomization
Receipt of live-virus vaccines within  days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Patients who received live vaccines or who have close contact with people who have received live vaccines within  days of day  of study treatment
Receipt of live vaccines against infectious diseases within  days;
Live or attenuated vaccines (other than experimental cancer vaccine therapy) within  days prior to receiving the first dose of MEDI-
Receipt of live vaccines with  weeks ( days) of study
Exposure to oral or IV antibiotics within  weeks or live attenuated vaccines within  weeks prior to randomization
Vaccination with live, attenuated vaccines within  weeks of first dose of this study
Patients who have received vaccination with live attenuated vaccines within  months prior to registration are not eligible
Live attenuated vaccines
Live attenuated vaccines
RECIPIENT: Live attenuated vaccines
Live attenuated vaccines within  days prior to leukapheresis.
Vaccination with live attenuated vaccines within  weeks of study agent administration
Subjects must not have received a live attenuated vaccine within  days before the first dose of investigational agent, and subjects, if enrolled, should not receive live vaccines during the study or for  days after the last dose of investigational agent.
Use of any live vaccines against infectious diseases within  weeks of initiation of study treatment
Recent receipt of live attenuated vaccines.
Received live vaccines within  days prior to enrollment